Logo

Shareholders OK Genome Therapeutics, Genesoft Merger

Feb 02, 2004

NEW YORK, Feb. 2 (GenomeWeb News) - Genome Therapeutics and Genesoft Pharmaceuticals said today that their shareholders approved the proposed merger of the two companies at two separate special meetings.

 

The companies said that they expect to close the transaction "as soon as practicable," but noted that the deal is still subject to certain conditions including the raising of $32 million to fund the combined entity.

 

The all-stock merger was first announced in November. The US Securities and Exchange Commission cleared a registration statement related to the merger in late December.

Breaking News
The Scan

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.

Clinical Trial Participants, Investigators Point to Importance of Clinical Trial Results Reporting in Canadian Study

Public reporting on clinical trial results is crucial, according to interviews with clinical trial participants, investigators, and organizers from three provinces appearing in BMJ Open.

Old Order Amish Analysis Highlights Autozygosity, Potential Ties to Blood Measures

Researchers in BMC Genomics see larger and more frequent runs-of-homozygosity in Old Order Amish participants, though only regional autozygosity coincided with two blood-based measures.

Suicidal Ideation-Linked Loci Identified Using Million Veteran Program Data

Researchers in PLOS Genetics identify risk variants within and across ancestry groups with a genome-wide association study involving veterans with or without a history of suicidal ideation.